Akoya Biosciences Inc

NASDAQ AKYA

Download Data

Akoya Biosciences Inc Retained Earnings To Equity Ratio 2 year CAGR for the quarter ending March 31, 2024: 170.90%

Akoya Biosciences Inc Retained Earnings To Equity Ratio 2 year CAGR is 170.90% for the quarter ending March 31, 2024. The retained earnings to equity ratio measures the proportion of a company's retained earnings to its shareholders' equity. It is calculated by dividing the retained earnings by the shareholders' equity. This ratio provides insights into the company's reinvestment of earnings and the level of retained profits relative to shareholders' equity. A higher ratio suggests a higher proportion of earnings being retained for reinvestment or future distribution to shareholders. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • Akoya Biosciences Inc Retained Earnings To Equity Ratio for the quarter ending March 31, 2023 was -4.40, a -317.17% change year over year.
  • Akoya Biosciences Inc Retained Earnings To Equity Ratio for the quarter ending March 31, 2022 was -1.06, a -203.43% change year over year.
  • Akoya Biosciences Inc Retained Earnings To Equity Ratio for the quarter ending March 31, 2021 was 1.02.
NASDAQ: AKYA

Akoya Biosciences Inc

CEO Mr. Brian McKelligon
IPO Date April 16, 2021
Location United States
Headquarters 100 Campus Drive, Marlborough, MA, United States, 01752
Employees 330
Sector Healthcare
Industry Medical instruments & supplies
Description

Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers analysis software partnerships ecosystem; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. It has a collaboration agreement with NeraCare that enables personalized therapy selection for early-stage melanoma patients. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.

Similar companies

ANGO

AngioDynamics Inc

NA

NA

PDEX

Pro-Dex Inc

NA

NA

StockViz Staff

September 19, 2024

Any question? Send us an email